Grants for Small businesses - Federal

This funding opportunity supports the establishment of a Coordinating Center to enhance diversity in the aging research workforce through targeted undergraduate education initiatives.

This program provides financial assistance to rural small businesses and agricultural producers for renewable energy projects and energy efficiency improvements to help reduce energy costs and promote sustainability.

demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the best and brightest in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the demonstrated ability of the individual named as the Principal Investigator (PI) in the application to go beyond conventional thinking in their field and the innovative contribution that the PI can make toward ending breast cancer. The application should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award. Individuals from other disciplines who apply novel concepts to breast cancer are encouraged to submit.The PI is encouraged to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. The PIs research team must include two or more breast cancer consumer advocates. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they may not be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 Era of Hope Scholar Award should not exceed $3.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $5.4M to fund approximately one Era of Hope Scholar Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides financial support to small businesses engaged in innovative research and development projects that have the potential for commercialization and significant societal impact.

It is the policy of my Administration to advance womens health research, close health disparities, and ensure that the gains we make in research laboratories are translated into real-world clinical benefits for women. It is also the policy of my Administration to ensure that women have access to high-quality, evidence-based health care and to improve health outcomes for women across their lifespans and throughout the country. President Joseph R. Biden, Jr., Executive Order 14120 on Advancing Womens Health Research and Innovation, 18 March 2024.In support of the Presidents Executive Order to advance womens health research, the PRORP is releasing this WHRA funding opportunity. The intent of the FY24 PRORP WHRA is to support research focused on orthopaedic issues faced by women serving in military settings, such as infantry and other physically demanding roles, who have sustained orthopaedic injuries. The overall goal of the WHRA is to address factors that contribute to the health and retention of women in military service. Although use of military populations, datasets, or samples are not required, the application should demonstrate how the proposed research relates to issues faced by women serving in military settings. The proposed research project should also include a well-formulated, testable hypothesis based on sound scientific rationale and logical reasoning.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.The PRORP encourages applications from a spectrum of research areas, including but not limited to translational and clinical research. The PRORP also welcomes qualitative research, population science, and health care services research specifically designed to understand the impact of orthopaedic injuries on female Service Members.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the PRORP WHRAs focus on orthopaedic injuries in women.A key feature of the PRORP WHRA is the relevance to female military and/or Veteran populations following orthopaedic injury. Inclusion of female military and/or Veteran populations is highly encouraged for applications proposing clinical research. Applicants proposing clinical studies in non-military and/or non-Veteran populations must justify the relevance of the proposed research to the military and/or Veteran communities. All applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.Research involving human subjects, human datasets, and human anatomical substances is permitted; however, the WHRA may not be used to conduct clinical trials. Applicants seeking support for a clinical trial should consider the FY24 PRORP Clinical Trial Award (Funding Opportunity Number HT942524PRORPCTA).Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 7, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.Encouraged Department of Defense (DOD) and/or VA Collaboration: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP WHRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.0M to fund approximately two WHRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides financial support for research projects that explore how policies on tobacco, alcohol, and cannabis use affect health disparities in underserved communities, with a focus on cancer prevention and community collaboration.

This funding opportunity provides financial support to a variety of organizations to improve coordinated care and research for individuals affected by a rare genetic disorder that causes abnormal blood vessel formation.

This funding opportunity supports researchers in studying and characterizing genetically modified mice that exhibit early life lethality or reduced viability, contributing to our understanding of gene function and its implications for human health.

This grant provides funding for large-scale, collaborative research projects that explore complex questions related to aging, requiring a multidisciplinary team and integration of various components across institutions.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R61/R33) mechanism to provide up to 2 years of R61 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

This funding opportunity is designed for U.S.-based small businesses to create engaging digital educational tools that teach pre-college students and teachers about biomedical sciences through interactive learning.

This funding opportunity supports innovative breast cancer research projects that aim to address critical challenges in prevention, diagnosis, and treatment, benefiting military personnel, veterans, and the general public.

This funding opportunity supports innovative research on how substance use disorders affect HIV infection and latency in the brain, encouraging collaboration among researchers in HIV, neuroscience, and addiction.

This grant provides funding to U.S.-based nonprofit organizations and for-profit businesses to help foreign governments adopt secure American digital technologies, enhancing their cybersecurity and infrastructure capabilities.

This funding opportunity provides financial support to organizations that will assist Botswana's Ministry of Health in implementing national HIV policies and improving care and mental health services for children and adolescents living with HIV.

This funding opportunity supports collaborative projects between academic institutions and industry to develop innovative bioengineering solutions that address significant biomedical challenges and improve medical practices.

Federal Awarding Agency Name: U.S. Department of Agriculture Natural Resources Conservation Service (NRCS)Notice of Funding Opportunity Title: Kentucky NRCS Easement Restoration and Management AssistanceNotice of Funding Opportunity Number: USDA-NRCS-KY-EASE-24NOFO0001320Assistance Listing: This program is listed in the Assistance Listings (previously referred to as the Catalog of Federal Financial Assistance) on Sam.gov under 10.072 Wetlands ReserveProgram and 10.931 Agricultural Conservation Easement Program, which can be found at: https://sam.gov/content/home.SAM is a web-based, government-wide application that collects, validates, stores, and disseminates business information about the federal government's trading partners in support of the contract awards, grants, and electronic payment processes.Notice of Funding Opportunity SummaryThe Natural Resources Conservation Service (NRCS), an agency under the United States Department of Agriculture (USDA), is seeking support from natural resource conservation partners to work together to help enhance conservation delivery in the Commonwealth of Kentucky. The overall intent of this announcement is to solicit partnerships to help enhance the implementation of key conservation objectives and priorities outlined further in this document.Proposals will be accepted from eligible entities as identified in Section C.1. of this announcement for competitive consideration of awards for projects between one (1) and (5) years in duration to deliver conservation programs and services in Kentucky. NRCS anticipates the amount of funding available for this announcement will be approximately $2,000,000 annually over a five year period (up to $10,000,000), which will be awarded to multiple recipients. All applicants must be capable of providing support throughout the Commonwealth of Kentucky. Entities may use this opportunity to request additional funding for existing Kentucky cooperative agreements.This notice identifies the objectives, eligibility criteria, and application instructions for projects. Proposals will be screened for completeness and compliance with the provisions of this notice. Incomplete and/or noncompliant applications may be eliminated from competition and notification of elimination will be sent to the applicant. The Kentucky State Conservationist reserves the right not to fund any or all applications. NRCS will accept applications under this notice for single or multiyear applications submitted by eligible entities.2For new users of Grants.gov, see Section D. of the full Notice of Funding Opportunity for information about steps required before submitting an application via Grants.gov.Key DatesApplicants must submit their applications via Grants.gov by 11:59 pm Eastern Time on June 30, 2024. For technical issues with Grants.gov, contact Grants.gov Applicant Support at 1-800-518-4726 or support@grants.gov. Awarding agency staff cannot support applicants regarding Grants.gov accounts.For inquiries specific to the content of the NFO requirements, contact the federal awarding agency contact (section G of this NFO). Please limit questions to those regarding specific information contained in this NFO (such as dates, page numbers, clarification of discrepancies, etc.). Questions related to eligibility, or the merits of a specific proposal will not be addressed.The agency anticipates making selections by August 1, 2024 and expects to execute awards by September 30,2024. These dates are estimates and are subject to change

This funding supports institutions in developing training programs for predoctoral and postdoctoral researchers in biomedical and clinical fields, with a focus on enhancing diversity and preparing trainees for successful research careers.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations.

The National Institute of Standards and Technology (NIST) invites FY 2023 NIST SBIR Phase I awardees to submit Phase II research applications under this Notice of Funding Opportunity (NOFO). Only FY 2023 NIST SBIR Phase I awardees are eligible to submit applications in response to this NOFO for Phase II of their projects. The Small Business Innovation Research (SBIR) program was originally established in 1982 by the Small Business Innovation Development Act (P.L. 97-219), codified at 15 U.S.C. § 638. The SBIR Program was then expanded and extended by the Small Business Research and Development (R&D) Enhancement Act of 1992 (P.L. 102-564), and received subsequent reauthorization and extensions, the most recent of which extends the SBIR program through 2025. (P.L. 117-183). Eleven Federal agencies implement SBIR by setting aside a portion of their extramural research and development budget each year to fund research applications from small science and technology-based firms. The statutory purpose of the SBIR Program is to strengthen the role of innovative small business concerns (SBCs) in Federally-funded research or research and development (R/R&D). Specific program goals are to: (1) stimulate technological innovation; (2) use small businesses to meet Federal R/R&D needs; (3) foster and encourage participation by socially and economically disadvantaged small businesses and by women-owned small businesses in technological innovation; and (4) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity, and economic growth.